REG - Feedback PLC - Grant of Options and PDMR dealing

FeedbackAnnouncement

10/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250710:nRSJ4480Qa&default-theme=true

RNS Number : 4480Q  Feedback PLC  10 July 2025

 

Feedback plc

 

Grant of Options and PDMR dealing

 

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical
infrastructure specialist, announces that it has granted a total of 254,117
options to subscribe for new ordinary shares of 1 penny each in the Company
("Ordinary Shares") under the Company's EMI Share Option Scheme (the
"Options") to a person discharging managerial responsibilities (PDMR) and
other employees, as detailed below.

 

The Options are being issued to appropriately incentivise and retain talent,
as well as to ensure their interests are aligned with that of the Company and
its Shareholders. The Options are exercisable at a price of 20 pence per
share, reflecting the price at which the Company last completed an equity
fundraise in November 2024 and representing a premium of 37.9 per cent to the
closing share price on the last trading day before this announcement.

 

219,073 Options are being granted to a PDMR as set out below. The Options will
vest in four equal tranches as follows:

 

·      25% vest in three equal sub-tranches annually (8.33% on each of
the first, second and third anniversary of grant of 10 July 2025)

·      25% vest on reported revenue of £8m

·      25% vest on reported revenue of £12m; and

·      25% vest on reported revenue of £20m

 

"Reported Revenue" is either:

·      a year's revenue reported in the full year audited financial
statements; or

·      12 months' revenue being H2 of the last full year audited
financial statements plus H1 of the last published interim financial
statements.

 

Options being granted to the PDMR which are subject to the vesting conditions
above:

 

                                               Number of Options granted  Total options held (including existing options)
 Mark Fletcher, Director of External Affairs*  219,073                    219,073

 

* Employed by Feedback Medical Limited, a 100% subsidiary of Feedback plc

 

In addition, 35,044 Options were awarded to four employees on 10 July 2025
with the same exercise price and vesting conditions as the PDMR as set out
above.

 

The Options are exercisable for a period of 5 years from the vesting date.

 

The Options represent in aggregate 0.6% of the Company's existing issued share
capital.

 

Following the grant of the Options and taking into account existing options,
the Company has a total of 4,042,913 options to subscribe for ordinary shares
in the Company in issue, representing 9.2% of the Company's issued share
capital at the date of this announcement.

 

The FCA notifications, made in accordance with the requirements of the EU
Market Abuse Regulation, are appended below.

 

Further information on Feedback and its products can be found on the Company's
website: https://feedbackmedical.com (https://feedbackmedical.com)

 

-Ends-

 

 

 

Enquiries:

 

 Feedback plc                                +44 (0) 20 3997 7634

 Tom Oakley, CEO                             IR@fbk.com (mailto:IR@fbk.com)

 Anesh Patel, CFO

 Panmure Liberum Limited (NOMAD and Broker)  +44 (0)20 7886 2500

 Emma Earl/Mark Rogers (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Walbrook PR Ltd;                            Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
                                             (mailto:feedbackplc@walbrookpr.com)
 Nick Rome/Joe Walker                        07748 325 236 or 07407 020 470

 

 

About Feedback plc

 

Feedback plc liberates the data and knowledge from multiple healthcare IT
systems and delivers better workflow to enable clinicians to communicate,
collaborate and provide the best healthcare for their patients. We connect
care settings with diagnostic and other relevant data to drive better, faster,
safer decision that improve outcomes for patients.

 

By linking different clinical systems together into a seamless view of the
patient, we can streamline patient pathways and deliver a digital health and
diagnostics record across multiple care providers.

 

Bleepa® is our communication and collaboration platform that displays
clinical results at a certified and regulated quality, which enables
multi-disciplinary team working and diagnostic-enhanced advice and guidance.
CareLocker® is our patient-facing platform that gives patients access and
control over their diagnostic and other clinical data.

 

The Company has a number of growth opportunities domestically and
internationally across a range of public and private healthcare markets
including the NHS. Our highly scalable software-as-a-service (SaaS) based
model is expected to provide increasing levels of revenue visibility as the
Company grows its customer base.

 

https://fbk.com (https://fbk.com)

 

Notification and public disclosure of transactions by Persons Discharging
Managerial Responsibilities under UK MAR

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Mark Fletcher

 2    Reason for the notification

 a)   Position/status                                              PDMR - Director of External Affairs of Feedback Medical Limited

 b)   Initial notification /Amendment                              Initial

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Feedback plc

 b)   LEI                                                          213800UGOF2GT2U2RV90

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 1 penny each

      Identification code

                                                                   GB00BJN59X09
 b)   Nature of the transaction                                    Grant of options to subscribe for Ordinary Shares

 c)   Price(s) and volume(s)                                       Price(s)  Volume(s)

                                                                   Nil       219,073

 

 d)   Aggregated information

      - Aggregated volume                                          N/A

      - Price
 e)   Date of the transaction                                      10 July 2025

 f)   Place of the transaction                                     Outside a trading venue

 

 

d)

 

Aggregated information

- Aggregated volume

- Price

 

N/A

 

e)

 

Date of the transaction

 

10 July 2025

 

f)

 

Place of the transaction

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHKKLFBEDLZBBL